anti-egfr antibody-drug conjugate abbv-637

Generic: Anti-EGFR Antibody-drug Conjugate ABBV-637

anti-egfr antibody-drug conjugate abbv-637: 1 clinical trial tracked.

What we can confirm

1 tracked trial

No verified listed developer

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.

BioSniper AIPage evidence connected

Prepared research question

What is verified about anti-egfr antibody-drug conjugate abbv-637, and what remains unknown?

Traceable citations · Unknowns marked

See linked entities and source evidence2 indications · 1 study sponsors

Clinical Trials (1)

Phase Ib Trial of ABBV-637 or ABBV-155 in Combination With ERAS-801 for Glioblastoma With Amplification of the Epidermal Growth Factor Receptor

Recruiting

Primary endpoint: Dose limiting toxicity (DLT)

InterventionalRandomizedopen60 targetStarted 2025-04Completion 2028-048 sites · United StatesMemorial Sloan Kettering Cancer Center

anti-egfr antibody-drug conjugate abbv-637 evidence translation